VALN

Valneva SE ADR is a biotechnology firm headquartered in Saint-Herblain, France, dedicated to the research, development, and commercialization of innovative vaccines aimed at addressing significant unmet medical needs in infectious diseases. The company boasts a promising pipeline that includes candidates for Lyme disease and chikungunya, illustrating its strategic focus on advanced scientific solutions to urgent health challenges. As global demand for effective vaccination strategies increases, Valneva's commitment to delivering unique vaccine products positions it favorably within the healthcare sector.